Veno-arterial extracorporeal membrane oxygenation (VA-ECMO) is a life-sustaining therapy for severe refractory cardiogenic shock. Although VA-ECMO provides various degrees of cardiopulmonary support, mortality rates remain high. Serum biomarkers have potential to identify the rising risk of mortality in patients receiving ECMO, but evidence supporting their prognostic value is inconsistent.
The post Investigating biomarkers associated with mortality in patients receiving VA-ECMO for cardiogenic shock: a systematic review appeared first on American Osteopathic Association.
